Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In 2019, PT141 (bremelanotide) was approved by the United States Food and Drug Administration (FDA) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
Regarding payment methods, we primarily accept T/T (Telegraphic Transfer)
Participants will receive two courses of the treatment spaced six months apart
Semaglutide mimics GLP-1 hormones, reducing appetite and slowing gastric emptying
US$ 26.43
US$ 24.80
US$ 26.39
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 21.33
US$ 24.13
US$ 24.50
US$ 20.99
US$ 27.97
US$ 20.86
